Pharmaron Beijing Co., Ltd. (SHE:300759)

Pharmaron Beijing Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	12,269	11,533	10,240	7,419	5,114
Other Revenue	6.4	4.61	26.19	24.48	19.55
Revenue	12,276	11,538	10,266	7,444	5,134
Revenue Growth (YoY)	6.39%	12.39%	37.92%	45.00%	36.63%
Cost of Revenue	8,091	7,422	6,502	4,768	3,215
Gross Profit	4,184	4,116	3,764	2,676	1,919
Selling, General & Admin	1,843	1,859	1,728	1,022	745.89
Research & Development	469.26	448.28	282.32	151.77	105.35
Other Operating Expenses	109.7	82.75	66.52	44.04	32.9
Operating Expenses	2,465	2,426	2,098	1,229	898.95
Operating Income	1,719	1,690	1,667	1,448	1,020
Interest Expense	-243.72	-182.19	-167.31	-83.07	-23.85
Interest & Investment Income	615.7	78.95	109.74	371.99	231.55
Currency Exchange Gain (Loss)	31.43	147	-42.39	-3.16	-131.23
Other Non Operating Income (Expenses)	-4.22	-3.61	-2.54	-1.39	-1.35
EBT Excluding Unusual Items	2,118	1,730	1,564	1,732	1,095
Impairment of Goodwill	-73.54	-	-	-	-
Gain (Loss) on Sale of Investments	1.54	18.75	68.09	119.59	190.86
Gain (Loss) on Sale of Assets	-33.67	-9.15	-15.3	-4.25	-7.28
Other Unusual Items	78.51	98.48	49.5	63.73	40.72
Pretax Income	2,091	1,838	1,666	1,911	1,319
Income Tax Expense	377.1	256.11	314.25	290.92	172.38
Earnings From Continuing Operations	1,714	1,582	1,352	1,620	1,147
Minority Interest in Earnings	79.19	19.32	22.47	40.95	25.39
Net Income	1,793	1,601	1,375	1,661	1,172
Net Income to Common	1,793	1,601	1,375	1,661	1,172
Net Income Growth	12.01%	16.48%	-17.24%	41.68%	114.25%
Shares Outstanding (Basic)	1,770	1,772	1,774	1,781	1,779
Shares Outstanding (Diluted)	1,773	1,775	1,776	1,820	1,785
Shares Change (YoY)	-0.11%	-0.05%	-2.40%	1.97%	20.06%
EPS (Basic)	1.01	0.90	0.78	0.93	0.66
EPS (Diluted)	1.01	0.90	0.77	0.91	0.66
EPS Growth	12.13%	16.54%	-15.21%	38.94%	78.46%
Free Cash Flow	536.02	-111.78	-807.04	-34.78	332.77
Free Cash Flow Per Share	0.30	-0.06	-0.45	-0.02	0.19
Dividend Per Share	0.200	0.200	0.200	0.200	0.133
Dividend Growth	-	-	-	50.04%	99.85%
Gross Margin	34.09%	35.67%	36.67%	35.95%	37.38%
Operating Margin	14.01%	14.64%	16.23%	19.45%	19.87%
Profit Margin	14.61%	13.88%	13.39%	22.31%	22.84%
Free Cash Flow Margin	4.37%	-0.97%	-7.86%	-0.47%	6.48%
EBITDA	2,583	2,431	2,227	1,852	1,325
EBITDA Margin	21.04%	21.07%	21.70%	24.88%	25.81%
D&A For EBITDA	863.3	741.2	560.76	404.64	304.85
EBIT	1,719	1,690	1,667	1,448	1,020
EBIT Margin	14.01%	14.64%	16.23%	19.45%	19.87%
Effective Tax Rate	18.03%	13.94%	18.86%	15.22%	13.06%
Revenue as Reported	12,276	11,538	10,266	7,444	5,134

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.